Formulation: A solid
Formal Name: (6S,9S,9aS)-hexahydro-2,9-dimethyl-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonooxy)phenyl]methyl]-8-(8-quinolinylmethyl)-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
Purity: ≥98%
Formula Markup: C33H35N6O7P
Formula Weight: 658,7
Shelf life (days): 1460
CAS Number: 1422253-38-0
Notes: PRI-724 is a prodrug form of the β-catenin/CREB-binding protein (CBP) inhibitor C-82 and a derivative of ICG-001 (Item No. 16257).{72534} It is cytotoxic to GES-1 gastric mucosal and HGC-27, MKN45, and AGS gastric cancer cells (IC50s = 16.53, 9.8, 44.28, and 3.48 µM, respectively) and enhances decreases in viability induced by lonidamine (Item No. 14640) or 2-deoxy-D-glucose (2-DG; Item No. 14325) in CAL 27, SCC-25, and BICR 22 tongue squamous carcinoma cells.{61917,67368} PRI-724 (0.4 mg/animal) reduces hepatic fibrosis in a mouse model of liver fibrosis induced by carbon tetrachloride (CCl4).{72534} It reduces the proliferation of CD4+ or CD8+ stem cell memory and central memory T cells in a rhesus macaque model of antiretroviral therapy-suppressed simian immunodeficiency virus (SIV) infection when administered at doses of 10 or 20 mg/kg per day.{72535}
English
Deutsch
